John Dodd, Ph.D.Vice President, Preclinical Development at Palatin Technologies, Inc.Speaker
Agenda Sessions
PL8177 OCD - Alignment of Receptor, Oral Formulation and Peptide for Maximal Therapeutic Ratio in IBD
On Demand - Premium OnlyView Session